These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
945 related articles for article (PubMed ID: 18520443)
1. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J; Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J; Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K; HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686 [TBL] [Abstract][Full Text] [Related]
4. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B; J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study. Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850 [TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B; Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750 [TBL] [Abstract][Full Text] [Related]
7. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863 [TBL] [Abstract][Full Text] [Related]
8. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Lopez-Cortes LF; Ruiz-Valderas R; Rivero A; Camacho A; Marquez-Solero M; Santos J; García-Lazaro M; Viciana P; Rodriguez-Baños J; Ocampo A Ther Drug Monit; 2007 Apr; 29(2):171-6. PubMed ID: 17417070 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375 [TBL] [Abstract][Full Text] [Related]
12. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064 [TBL] [Abstract][Full Text] [Related]
13. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618 [TBL] [Abstract][Full Text] [Related]
16. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187 [TBL] [Abstract][Full Text] [Related]
17. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients. Marin-Niebla A; Lopez-Cortes LF; Ruiz-Valderas R; Viciana P; Mata R; Gutierrez A; Pascual R; Rodriguez M Antimicrob Agents Chemother; 2007 Jun; 51(6):2035-42. PubMed ID: 17371813 [TBL] [Abstract][Full Text] [Related]
18. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. Rudin C; Burri M; Shen Y; Rode R; Nadal D; ; Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386 [TBL] [Abstract][Full Text] [Related]
19. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Dragsted UB; Gerstoft J; Youle M; Fox Z; Losso M; Benetucci J; Jayaweera DT; Rieger A; Bruun JN; Castagna A; Gazzard B; Walmsley S; Hill A; Lundgren JD; Antivir Ther; 2005; 10(6):735-43. PubMed ID: 16218173 [TBL] [Abstract][Full Text] [Related]